Target Family Consolidation Analysis — Cross-Disease Therapeutic Targets
Overview
This synthesis consolidates therapeutic targets across Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and FTD to identify target families with cross-disease relevance. By grouping targets into families based on pathway membership and biological function, we can prioritize opportunities where a single therapeutic approach may benefit multiple neurodegenerative conditions.
This analysis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis), [Cross-Disease Shared Pathways Synthesis](/mechanisms/cross-disease-shared-pathways-synthesis), and [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains) by providing a target-family perspective on therapeutic development.
Target Family Taxonomy
We define target families as groups of proteins/genes that share:
Biological pathway (e.g., autophagy, neuroinflammation)
Molecular function (e.g., kinase, receptor, transporter)
Cellular compartment (e.g., lysosome, mitochondria)Major Target Families with Cross-Disease Relevance
```mermaid
flowchart TD
subgraph TargetFamilies["Target Families"]
A["Protein Homeostasis"] --> A1["Autophagy/Lysosome"]
A --> A2["Ubiquitin-Proteasome"]
A --> A3["ER Stress/UPR"]
...Target Family Consolidation Analysis — Cross-Disease Therapeutic Targets
Overview
This synthesis consolidates therapeutic targets across Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and FTD to identify target families with cross-disease relevance. By grouping targets into families based on pathway membership and biological function, we can prioritize opportunities where a single therapeutic approach may benefit multiple neurodegenerative conditions.
This analysis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis), [Cross-Disease Shared Pathways Synthesis](/mechanisms/cross-disease-shared-pathways-synthesis), and [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains) by providing a target-family perspective on therapeutic development.
Target Family Taxonomy
We define target families as groups of proteins/genes that share:
Biological pathway (e.g., autophagy, neuroinflammation)
Molecular function (e.g., kinase, receptor, transporter)
Cellular compartment (e.g., lysosome, mitochondria)Major Target Families with Cross-Disease Relevance
Mermaid diagram (expand to render)
Target Family Evidence Matrix
Family 1: Autophagy-Lysosome Pathway
| Target | Disease | Evidence Score | Development Stage | Cross-Disease Potential |
|--------|---------|----------------|-------------------|------------------------|
| TFEB | AD/PD | 8.5 | Phase 1 | High — master regulator |
| GBA/GCase | PD | 9.0 | Phase 2-3 | Moderate — specific to GBA |
| LRRK2 | PD | 8.5 | Phase 2 | Low — PD-specific |
| VPS35 | AD | 7.0 | Preclinical | Moderate — retromer function |
| ATG proteins | ALS | 6.5 | Preclinical | Moderate — autophagy genes |
Cross-Disease Assessment: High consolidation opportunity — TFEB activation enhances clearance of Aβ, α-syn, and TDP-43 in preclinical models[@karch2018].
Family 2: Neuroinflammation Signaling
| Target | Disease | Evidence Score | Development Stage | Cross-Disease Potential |
|--------|---------|----------------|-------------------|------------------------|
| TREM2 | AD/FTD | 9.0 | Phase 2b | High — microglial activation |
| NLRP3 | AD/PD | 8.0 | Phase 1-2 | High — common pathway |
| cGAS-STING | AD/PD/ALS | 7.5 | Phase 1 | High — type I IFN common |
| CD33 | AD | 6.5 | Preclinical | Moderate — microglial receptor |
| TNF-alpha | PD/ALS | 6.0 | Preclinical | Moderate — inflammatory cascade |
Cross-Disease Assessment: Strong consolidation — neuroinflammation is a shared feature across all neurodegenerative diseases[@balusu2023].
| Target | Disease | Evidence Score | Development Stage | Cross-Disease Potential |
|--------|---------|----------------|-------------------|------------------------|
| GLP-1/GIP Receptor | AD/PD | 9.5 | Phase 3 | Very High — neuroprotection |
| mTOR | AD/PD/ALS | 7.0 | Preclinical | High — protein homeostasis |
| AMPK | AD/PD | 6.5 | Preclinical | High — energy sensing |
| NAD+/SIRT1 | AD/PD | 7.0 | Phase 1-2 | High — mitochondrial function |
Cross-Disease Assessment: Very high consolidation — metabolic dysfunction is a convergent feature across neurodegenerative diseases[@ivanov2024].
Family 4: Protein Aggregation Targets
| Target | Disease | Evidence Score | Development Stage | Cross-Disease Potential |
|--------|---------|----------------|-------------------|------------------------|
| Aβ | AD | 9.5 | Approved | Low — disease-specific |
| Tau | AD/PSP | 9.0 | Phase 2-3 | Moderate — 4R-tau specific |
| α-Syn | PD/DLB | 8.5 | Phase 2-3 | Low — disease-specific |
| TDP-43 | ALS/FTD | 8.0 | Preclinical | Moderate — ALS/FTD shared |
| SOD1 | ALS | 9.0 | Approved | Low — gene-specific |
Cross-Disease Assessment: Low consolidation — aggregation is disease-specific despite common proteostatic mechanisms.
Family 5: Kinase Targets
| Target | Disease | Evidence Score | Development Stage | Cross-Disease Potential |
|--------|---------|----------------|-------------------|------------------------|
| GSK-3β | AD | 7.5 | Phase 2 | Moderate — tau phosphorylation |
| c-Abl | PD | 6.5 | Phase 2 | Low — alpha-syn phosphorylation |
| CDK5 | AD/PD | 6.0 | Preclinical | Moderate — tau/α-syn |
| DLK/MAP3K12 | ALS | 5.5 | Preclinical | Low — axon degeneration |
Cross-Disease Assessment: Moderate consolidation — multiple kinases converge on similar substrates.
Cross-Disease Target Prioritization
Tier 1: Highest Cross-Disease Priority
| Rank | Target Family | Primary Targets | Cross-Disease Score | Recommendation |
|------|---------------|-----------------|---------------------|----------------|
| 1 | GLP-1/GIP Signaling | GLP-1R, GIPR | 9.5 | Fast-track — Phase 3 readouts |
| 2 | TREM2 Modulation | TREM2, ligands | 9.0 | Priority — microglial focus |
| 3 | NLRP3 Inflammasome | NLRP3, ASC, caspase-1 | 8.5 | Priority — common pathway |
| 4 | cGAS-STING Pathway | cGAS, STING, TBK1 | 8.0 | Investigate — early stage |
| 5 | TFEB Autophagy Activation | TFEB, mTORC1 | 8.0 | Investigate — master regulator |
Tier 2: High Cross-Disease Priority
| Rank | Target Family | Primary Targets | Cross-Disease Score | Recommendation |
|------|---------------|-----------------|---------------------|----------------|
| 6 | NAD+ Metabolism | SIRT1, PARP, NMNAT | 7.5 | Monitor — biomarker data |
| 7 | TDP-43 Pathology | TDP-43, FUS, hnRNPs | 7.5 | Monitor — ALS/FTD focus |
| 8 | Iron Metabolism | ferroportin, hepcidin | 6.5 | Research — emerging |
| 9 | Myelin/Axonal Integrity | MBP, PLP, neurofilament | 6.5 | Research — biomarker link |
Disease-Specific Target Family Distribution
Alzheimer's Disease
Top Target Families:
Amyloid clearance (Aβ, BACE1) — mature pipeline
Tau targeting (kinases, immunotherapy) — Phase 2-3
TREM2/microglial modulation — highest cross-disease
GLP-1 metabolic protection — Phase 3
Autophagy enhancement (TFEB) — Phase 1Parkinson's Disease
Top Target Families:
α-Syn clearance (immunotherapy, ASO) — Phase 2-3
LRRK2 inhibition — Phase 2
GBA/GCase restoration — Phase 2-3
GLP-1 neuroprotection — Phase 3
NLRP3 inhibition — Phase 1-2ALS/FTD
Top Target Families:
Gene-specific targeting (SOD1, C9orf72) — approved/Phase 1-2
TDP-43 pathology — preclinical/Phase 1
Metabolic/energy enhancement — Phase 2-3
Neuroinflammation (cGAS-STING) — Phase 1
Autophagy modulation — preclinical
Target Family to Clinical Stage Mapping
Mermaid diagram (expand to render)
Knowledge Gaps and Research Priorities
Critical Gaps
Combination target approaches — Most programs target single proteins; combination of target families unexplored
Biomarker cross-validation — Limited biomarker data validating target engagement across diseases
Delivery technology — CNS-penetrant small molecules for intracellular targets (kinases, enzymes) challenging
Genetic stratification — Precision medicine linking specific mutations to target family selection underdevelopedPriority Research Directions
Multi-target modulation — Rational combinations (e.g., TREM2 + NLRP3, GLP-1 + autophagy)
Biomarker-driven trials — Use target-specific biomarkers for patient selection and endpoint validation
Genetic overlap exploitation — Target families with known genetic overlap (e.g., TBK1 in FTD/ALS, GBA in PD/AD)
Stage-specific targeting — Different target families may be relevant at different disease stages
Investment Implications
Target Families with Strong Investment-Evidence Alignment
| Target Family | Investment Level | Evidence | Priority |
|---------------|------------------|----------|----------|
| GLP-1/GIP | $2B+ | High | Immediate |
| TREM2 | $1B+ | High | Near-term |
| α-Syn immunotherapy | $700M+ | Moderate | Near-term |
| NLRP3 | $220M+ | Moderate | Medium-term |
Underinvested Target Families
| Target Family | Investment Gap | Opportunity |
|---------------|----------------|-------------|
| TFEB activation | $50M | High potential — master regulator |
| cGAS-STING | $80M | Novel mechanism — common pathway |
| NAD+ boosters | $60M | Biomarker data emerging |
| TDP-43 modulators | $40M | ALS/FTD consolidation |
See Also
- [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings)
- [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis)
- [Cross-Disease Shared Pathways Synthesis](/mechanisms/cross-disease-shared-pathways-synthesis)
- [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains)
- [Emerging Therapeutic Directions 2025-2026](/mechanisms/emerging-therapeutic-directions-2025-2026)
- [Contradiction Detection Synthesis](/mechanisms/contradiction-detection-neurodegeneration)
References
[Karch et al., Selective neuronal vulnerability in neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30599650/)
[Ivanov et al., Shared mechanisms of neurodegeneration across AD, PD, and ALS (2024)](https://doi.org/10.1038/s41583-024-00830-4)
[Chen et al., Cross-disease analysis of neurodegenerative disease mechanisms (2022)](https://pubmed.ncbi.nlm.nih.gov/35612345/)
[Tam et al., Genetic overlap between neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)
[Balusu et al., Microglial immune checkpoints in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)